← Leaderboards
Theodoros Kelesidis
University Of California Los Angeles
$4,316,026
Attributed
$4,527,776
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $710.5K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,527,776 · 7
By mechanism
R01$1,997,952 · 1
R21$1,303,500 · 3
K08$914,824 · 1
R03$311,500 · 2
Top collaborators
- Srinivasa Reddy2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Ronald T Mitsuyasu$121,811,876
- Otoniel Martinez-Maza$22,455,072
- Srinivasa Reddy$11,348,036
- Daniel Kaufman$8,790,517
- Gail E Wyatt$23,971,522
Others in their field
Top investigators on “Inflammation”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$89,523,713
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Randall J Bateman · Washington University$64,707,456
- Peter Scott Heeger · Case Western Reserve University$56,547,884
Research focus
InflammationMorbidity - Disease RateInfectionInnovationPersonsDesignPathogenesisMacrophageAntioxidantsChronicHiv-1MonocytePublic HealthResearch ProposalsCellsCardiovascular DiseasesComorbidityMimeticsIn VivoOxidized LipidComplexLipoproteinsImmune ActivationNovel Therapeutics
Grant awards (22)
Mitoquinone/mitoquinol mesylate as oral and safe Postexposure Prophylaxis for Covid-19$205,000
R21 · FY2025 · AI · contact PI
Mitoquinone/mitoquinol mesylate as oral and safe Postexposure Prophylaxis for Covid-19$246,000
R21 · FY2023 · AI · contact PI
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV$335,399
R01 · FY2022 · AG · contact PI
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV$1
R01 · FY2022 · AG · contact PI
Preclinical studies to establish the combination of apoA-I mimetic peptides and statins as novel therapy for COVID-19$335,400
R01 · FY2021 · AG · contact PI
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV$335,400
R01 · FY2021 · AG · contact PI
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV$335,400
R01 · FY2020 · AG · contact PI
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV$335,400
R01 · FY2019 · AG · contact PI
In vivo modelling of therapeutic strategies for prevention of HIV-related fibrosis and fatty liver disease in chronic treated HIV-1 infection$195,000
R21 · FY2019 · AI · contact PI
Humanized mice as a model to study novel therapies for HIV-Associated Neurocognitive Disorders (HAND) in elderly HIV-1 infected individuals$78,000
R03 · FY2019 · AG · contact PI
Elucidating the impact of molecular signatures of immune senescence on aging in chronic treated HIV$78,000
R03 · FY2019 · AG · contact PI
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV$320,952
R01 · FY2018 · AG · contact PI
In vivo modelling of therapeutic strategies for prevention of HIV-related fibrosis and fatty liver disease in chronic treated HIV-1 infection$234,000
R21 · FY2018 · AI · contact PI
Elucidating the impact of molecular signatures of immune senescence on aging in chronic treated HIV$78,000
R03 · FY2018 · AG · contact PI
Humanized mice as a model to study novel therapies for HIV-Associated Neurocognitive Disorders (HAND) in elderly HIV-1 infected individuals$77,500
R03 · FY2018 · AG · contact PI
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosis$201,960
K08 · FY2017 · AI · contact PI
Humanized mice as a model to study the role of oxidized lipids in HIV-related cardiovascular disease$192,500
R21 · FY2017 · HL · contact PI
Humanized mice as a model to study the role of oxidized lipids in HIV-related cardiovascular disease$231,000
R21 · FY2016 · HL · contact PI
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosis$178,016
K08 · FY2016 · AI · contact PI
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosis$178,016
K08 · FY2015 · AI · contact PI
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosis$178,416
K08 · FY2014 · AI · contact PI
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosis$178,416
K08 · FY2013 · AI · contact PI